July 26, 2020
4 min watch
Save
VIDEO: Iluvien delays DR progression in patients lost to follow-up
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video from the virtual American Society of Retina Specialists meeting, Caesar Luo, MD, discusses the progression of retinal disease in eyes of patients lost to follow-up for at least 6 months.
The patients with the Iluvien fluocinolone acetonide implant (Alimera Sciences) showed less progression to severe disease than patients treated with anti-VEGF therapy.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.